AR050932A1 - BICYCLE AMIDAS AS CINASE INHIBITORS - Google Patents
BICYCLE AMIDAS AS CINASE INHIBITORSInfo
- Publication number
- AR050932A1 AR050932A1 ARP050103817A ARP050103817A AR050932A1 AR 050932 A1 AR050932 A1 AR 050932A1 AR P050103817 A ARP050103817 A AR P050103817A AR P050103817 A ARP050103817 A AR P050103817A AR 050932 A1 AR050932 A1 AR 050932A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- lower alkyl
- alkylene
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La presente se refiere a compuestos de formula (1), a composiciones farmacéuticas que los comprenden y a su uso en el tratamiento de enfermedades dependientes de cinasa de proteína, especialmente enfermedades proliferativas, en particular enfermedades tumorales. Reivindicacion 1: Un compuesto de la formula (1) en donde R1 es H, halogeno, ciano, -C0-C7-O-R3; -C0-C7-NR4R5, o -C(=O)-R6; R2 es cicloalquilo C3-8 substituido; arilo substituido; o heterociclilo substituido; R3 es H o alquilo inferior no substituido o substituido; R4 y R5 se seleccionan independientemente del grupo que consiste de H, alquilo inferior no substituido o substituido, alquilcarbonilo inferior, en donde la porcion de alquilo inferior está opcionalmente substituida, y alcoxi-carbonilo inferior, en donde la porcion alquilo inferior está opcionalmente substituid; R6 es H, alquilo inferior no substituido o substituido, alcoxi inferior, en donde la porcion de alquilo inferior está opcionalmente substituida; amino no substituido, mono- o di-substituido; A, B, y X se seleccionan independientemente de =C(R7)- o N; E, G y T se seleccionan independientemente de =C(R9)- o N; R7 y R8 se seleccionan independientemente del grupo que consiste de H, halogeno y alquilo inferior no substituido o substituido; Y es -O-, -S-, -S(O)-, -S(O)2-, -CH2-, -CH2CH2-, -CH=CH- o -C:::C-; Z es CH o N y Q es alquileno C1-4 o alquenileno C2-4, en donde el alquileno C1-4 o el alquenileno C2-4 opcionalmente puede estar substituido y en donde uno o más de los átomos de C de dicha cadena de alquileno C1-4 o el alquenileno C2-4 opcionalmente puede ser reemplazado por un átomo heterogéneo independientemente seleccionado de H, O y S; y el enlace entre Q y Z caracterizado por una línea punteada es un enlace individual; siempre que si Z es N, Q no es un alquileno C2-4 no ramificado no substituido; o Z es C y Q como se definio anteriormente en donde el enlace entre Q y Z caracterizado por la línea punteada es un enlace doble; y W no está presente o es alquileno C1-3, o un tautomero del mismo, o una sal del mismo.This refers to compounds of formula (1), pharmaceutical compositions comprising them and their use in the treatment of protein kinase dependent diseases, especially proliferative diseases, in particular tumor diseases. Claim 1: A compound of the formula (1) wherein R1 is H, halogen, cyano, -C0-C7-O-R3; -C0-C7-NR4R5, or -C (= O) -R6; R2 is substituted C3-8 cycloalkyl; substituted aryl; or substituted heterocyclyl; R3 is H or unsubstituted or substituted lower alkyl; R4 and R5 are independently selected from the group consisting of H, unsubstituted or substituted lower alkyl, lower alkylcarbonyl, wherein the lower alkyl portion is optionally substituted, and lower alkoxycarbonyl, wherein the lower alkyl portion is optionally substituted; R6 is H, unsubstituted or substituted lower alkyl, lower alkoxy, wherein the lower alkyl portion is optionally substituted; unsubstituted, mono- or di-substituted amino; A, B, and X are independently selected from = C (R7) - or N; E, G and T are independently selected from = C (R9) - or N; R7 and R8 are independently selected from the group consisting of H, halogen and unsubstituted or substituted lower alkyl; Y is -O-, -S-, -S (O) -, -S (O) 2-, -CH2-, -CH2CH2-, -CH = CH- or -C ::: C-; Z is CH or N and Q is C1-4 alkylene or C2-4 alkenylene, wherein C1-4 alkylene or C2-4 alkenylene may optionally be substituted and where one or more of the C atoms of said chain of C1-4 alkylene or C2-4 alkenylene may optionally be replaced by a heterogeneous atom independently selected from H, O and S; and the link between Q and Z characterized by a dotted line is an individual link; provided that if Z is N, Q is not an unsubstituted unsubstituted C2-4 alkylene; or Z is C and Q as defined above where the link between Q and Z characterized by the dotted line is a double bond; and W is not present or is C1-3 alkylene, or a tautomer thereof, or a salt thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0420520A GB0420520D0 (en) | 2004-09-15 | 2004-09-15 | Organic compounds |
GB0511687A GB0511687D0 (en) | 2005-06-08 | 2005-06-08 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050932A1 true AR050932A1 (en) | 2006-12-06 |
Family
ID=35705284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103817A AR050932A1 (en) | 2004-09-15 | 2005-09-13 | BICYCLE AMIDAS AS CINASE INHIBITORS |
Country Status (23)
Country | Link |
---|---|
US (2) | US8026247B2 (en) |
EP (1) | EP1794149A2 (en) |
JP (2) | JP4950889B2 (en) |
KR (3) | KR20100111324A (en) |
CN (1) | CN101693709A (en) |
AR (1) | AR050932A1 (en) |
AU (2) | AU2005310968C1 (en) |
BR (1) | BRPI0515446A (en) |
CA (2) | CA2574829C (en) |
EC (1) | ECSP077324A (en) |
GT (1) | GT200500260A (en) |
IL (1) | IL181720A0 (en) |
MA (1) | MA28876B1 (en) |
MX (1) | MX2007003013A (en) |
MY (2) | MY147640A (en) |
NO (1) | NO20071875L (en) |
NZ (3) | NZ587806A (en) |
PE (1) | PE20060664A1 (en) |
RU (3) | RU2416611C2 (en) |
SG (1) | SG155921A1 (en) |
TN (1) | TNSN07093A1 (en) |
TW (1) | TW200626576A (en) |
WO (1) | WO2006059234A2 (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1667964T1 (en) | 2003-09-19 | 2009-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
MY147518A (en) | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
PE20060664A1 (en) | 2004-09-15 | 2006-08-04 | Novartis Ag | BICYCLE AMIDAS AS KINASE INHIBITORS |
GT200600411A (en) * | 2005-09-13 | 2007-05-21 | Novartis Ag | COMBINATIONS THAT INCLUDE AN INHIBITOR OF THE RECEIVER OF THE VASCULAR ENDOTELIAL GROWTH FACTOR |
JO3006B1 (en) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | Novel Lysine Salts of 4-((Phenoxy Alkyl)Thio)-Phenoxy Acetic Acid Derivatives |
BRPI0619514A2 (en) | 2005-12-08 | 2011-10-04 | Millennium Pharm Inc | bicyclic compounds with kinase inhibitory activity, pharmaceutical composition containing them and use of said compounds |
GB0604937D0 (en) * | 2006-03-10 | 2006-04-19 | Novartis Ag | Organic compounds |
GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
KR20090023561A (en) | 2006-04-07 | 2009-03-05 | 노파르티스 아게 | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315ile kinase inhibitor |
PE20080188A1 (en) | 2006-04-18 | 2008-03-10 | Janssen Pharmaceutica Nv | DERIVATIVES OF BENZOAZEPINE-OXY-ACETIC ACID AS PPAR-DELTA AGONISTS USED TO INCREASE HDL-C, REDUCE LDL-C AND REDUCE CHOLESTEROL |
WO2008031835A2 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Method of treating autoimmune diseases using vegf-pathway inhibitors |
ES2702362T3 (en) | 2007-01-31 | 2019-02-28 | Ym Biosciences Australia Pty | Compounds based on thiopyrimidine and uses thereof |
AU2008237839B2 (en) * | 2007-04-17 | 2012-02-02 | Novartis Ag | Ethers of naphtalene carboxylic acid amides as cancer cure |
WO2008132505A1 (en) * | 2007-04-27 | 2008-11-06 | Astrazeneca Ab | N' - (phenyl) -n- (morpholin-4-yl-pyridin-2-yl) -pyrimidine-2, 4-diamine derivatives as ephb4 kinase inhibitors for the treatment of proliferative conditions |
CL2008002786A1 (en) * | 2007-09-20 | 2009-05-15 | Novartis Ag | Pharmaceutically acceptable cake, formed by lyophilization, comprising: n-hydroxy-3- [4 - [[[2- (2-methyl-1h-indol-3-yl] -ethyl] -amino] -methyl] -phenyl] -2e-2-propenamide or a salt, a selected pH regulator of lactate or lactic acid, phosphate or phosphoric acid or a combination and a bulking agent; manufacturing process. |
PT2350075E (en) | 2008-09-22 | 2014-06-09 | Array Biopharma Inc | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
JO3265B1 (en) | 2008-12-09 | 2018-09-16 | Novartis Ag | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease |
US20110112121A1 (en) | 2009-07-06 | 2011-05-12 | Joerg Berghausen | Pharmaceutical Compositions and Solid Forms |
AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
MX365251B (en) | 2010-05-20 | 2019-05-28 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors. |
AU2011322597B2 (en) | 2010-10-27 | 2015-09-10 | Novartis Ag | Dosing regimes for the treatment of ocular vascular disease |
GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
JP2014505052A (en) * | 2011-01-06 | 2014-02-27 | ベータ ファルマ カナダ インコーポレーテッド | New urea for cancer treatment and prevention |
GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
SG10201601516QA (en) | 2011-01-21 | 2016-03-30 | Eisai R&D Man Co Ltd | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives |
GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
JPWO2015064764A1 (en) * | 2013-11-01 | 2017-03-09 | 宇部興産株式会社 | Allyloyl (oxy or amino) pentafluorosulfanylbenzene compound, pharmaceutically acceptable salts thereof, and prodrugs thereof |
CN104860885B (en) * | 2014-02-24 | 2017-11-17 | 中国科学院上海药物研究所 | Naphthoyl aminated compounds, preparation method and use |
CN113354649A (en) | 2014-11-16 | 2021-09-07 | 阵列生物制药公司 | Novel crystal form |
US20180186755A1 (en) * | 2015-07-01 | 2018-07-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
PL3322706T3 (en) | 2015-07-16 | 2021-07-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
CA3003153A1 (en) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
KR20210010652A (en) | 2016-04-04 | 2021-01-27 | 록쏘 온콜로지, 인코포레이티드 | Methods of treating pediatric cancers |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
PE20181888A1 (en) | 2016-04-04 | 2018-12-11 | Loxo Oncology Inc | LIQUID FORMULATIONS OF (S) -N- (5 - ((R) -2- (2,5-DIFLUOROPHENYL) -PYRROLIDIN-1-IL) -PYRAZOLE [1,5-A] PYRIMIDIN-3-IL) -3 -HYDROXYPYRROLIDINE-1-CARBOXAMIDE |
RU2745953C2 (en) | 2016-05-18 | 2021-04-05 | Локсо Онколоджи, Инк. | Method for making (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrolidine-1-carboxamide and its salts |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
TWI802635B (en) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
TW201932464A (en) | 2018-01-18 | 2019-08-16 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolyl[4,3-C]pyridine compounds as RET kinase inhibitors |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
KR102653681B1 (en) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | SPRAY-DRIED DISPERSIONS AND FORMULATIONS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUORO PROPAN-2-YL)-lH-PYRAZOLE-4-CARBOXAMIDE |
ES2922314T3 (en) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Fused Heterocyclic Compounds as RET Kinase Inhibitors |
EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
CN113490666A (en) | 2018-12-19 | 2021-10-08 | 奥瑞生物药品公司 | Substituted pyrazolo [1,5-A ] pyridine compounds as inhibitors of FGFR tyrosine kinases |
WO2021134004A1 (en) | 2019-12-27 | 2021-07-01 | Schrodinger, Inc. | Cyclic compounds and methods of using same |
CN115803316A (en) * | 2020-07-23 | 2023-03-14 | 深圳晶泰科技有限公司 | Pyridone compound and preparation method and application thereof |
WO2022055963A1 (en) | 2020-09-10 | 2022-03-17 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
WO2022164789A1 (en) | 2021-01-26 | 2022-08-04 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disoders |
TW202300150A (en) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | Cyclic compounds and methods of using same |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO4950519A1 (en) * | 1997-02-13 | 2000-09-01 | Novartis Ag | PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION |
ES2257313T3 (en) | 1999-08-27 | 2006-08-01 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | INDOLINONES REPLACED IN QUALITY OF TYROSINE QUINASA INHIBITORS. |
WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
ES2318649T3 (en) | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | PROCEDURE FOR PREPARATION OF DERIVATIVES OF 4-FENOXI QUINOLINAS. |
MXPA04007832A (en) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aryl ureas with angiogenesis inhibiting activity. |
PE20040522A1 (en) | 2002-05-29 | 2004-09-28 | Novartis Ag | DIARYLUREA DERIVATIVES DEPENDENT ON PROTEIN KINASE |
JP4183193B2 (en) * | 2002-08-30 | 2008-11-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Nitrogen-containing aromatic ring derivatives |
TW200418466A (en) * | 2002-11-06 | 2004-10-01 | Smithkline Beecham Corp | Chemical compounds |
CA2536788A1 (en) * | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
JP4895811B2 (en) | 2003-09-11 | 2012-03-14 | ケミア,インコーポレイテッド | Cytokine inhibitor |
EA011402B1 (en) | 2004-01-23 | 2009-02-27 | Эмджен Инк. | Nitrogen-containing heterocyclic compounds and pharmaceutical use thereof |
JP4865702B2 (en) | 2004-05-03 | 2012-02-01 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Cytokine inhibitor |
PE20060664A1 (en) | 2004-09-15 | 2006-08-04 | Novartis Ag | BICYCLE AMIDAS AS KINASE INHIBITORS |
GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
-
2005
- 2005-09-12 PE PE2005001058A patent/PE20060664A1/en not_active Application Discontinuation
- 2005-09-13 MY MYPI20054290A patent/MY147640A/en unknown
- 2005-09-13 MY MYPI20092342A patent/MY148246A/en unknown
- 2005-09-13 AR ARP050103817A patent/AR050932A1/en not_active Application Discontinuation
- 2005-09-14 RU RU2007114124/04A patent/RU2416611C2/en not_active IP Right Cessation
- 2005-09-14 RU RU2010138639/04A patent/RU2448103C2/en not_active IP Right Cessation
- 2005-09-14 KR KR1020107020440A patent/KR20100111324A/en not_active Application Discontinuation
- 2005-09-14 US US11/575,025 patent/US8026247B2/en not_active Expired - Fee Related
- 2005-09-14 CN CN200910205861A patent/CN101693709A/en active Pending
- 2005-09-14 SG SG200906116-9A patent/SG155921A1/en unknown
- 2005-09-14 NZ NZ587806A patent/NZ587806A/en not_active IP Right Cessation
- 2005-09-14 NZ NZ587805A patent/NZ587805A/en not_active IP Right Cessation
- 2005-09-14 CA CA2574829A patent/CA2574829C/en not_active Expired - Fee Related
- 2005-09-14 EP EP05850758A patent/EP1794149A2/en not_active Withdrawn
- 2005-09-14 GT GT200500260A patent/GT200500260A/en unknown
- 2005-09-14 CA CA2738383A patent/CA2738383A1/en not_active Abandoned
- 2005-09-14 KR KR1020107020439A patent/KR20100103890A/en active IP Right Grant
- 2005-09-14 KR KR1020077005959A patent/KR20070052309A/en active IP Right Grant
- 2005-09-14 BR BRPI0515446-4A patent/BRPI0515446A/en not_active IP Right Cessation
- 2005-09-14 MX MX2007003013A patent/MX2007003013A/en active IP Right Grant
- 2005-09-14 AU AU2005310968A patent/AU2005310968C1/en not_active Ceased
- 2005-09-14 JP JP2007530802A patent/JP4950889B2/en not_active Expired - Fee Related
- 2005-09-14 WO PCT/IB2005/004030 patent/WO2006059234A2/en active Application Filing
- 2005-09-14 NZ NZ553094A patent/NZ553094A/en not_active IP Right Cessation
- 2005-09-14 TW TW094131697A patent/TW200626576A/en unknown
-
2007
- 2007-03-05 IL IL181720A patent/IL181720A0/en unknown
- 2007-03-14 EC EC2007007324A patent/ECSP077324A/en unknown
- 2007-03-14 TN TNP2007000093A patent/TNSN07093A1/en unknown
- 2007-03-26 MA MA29778A patent/MA28876B1/en unknown
- 2007-04-13 NO NO20071875A patent/NO20071875L/en not_active Application Discontinuation
-
2009
- 2009-03-18 AU AU2009201090A patent/AU2009201090B2/en not_active Ceased
- 2009-12-30 RU RU2009149216/04A patent/RU2009149216A/en unknown
-
2011
- 2011-03-08 JP JP2011050331A patent/JP2011148808A/en active Pending
- 2011-08-17 US US13/211,765 patent/US20110301157A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050932A1 (en) | BICYCLE AMIDAS AS CINASE INHIBITORS | |
AR062360A1 (en) | HETEROCICLIC DERIVATIVES THAT MODULATE THE ACTIVITY OF ESTEAROIL-COA-DESATURASA | |
AR047076A1 (en) | PIRROLOTRIAZINE COMPOUNDS AS THYROSINE KINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS | |
AR056194A1 (en) | COMBINATIONS THAT INCLUDE AN INHIBITOR OF THE RECEIVER OF THE VASCULAR ENDOTELIAL GROWTH FACTOR | |
AR049319A1 (en) | DERIVATIVES OF 6-HETEROARILFENANTRIDINAS | |
UY29457A1 (en) | NEW COMPOUNDS OF AMINOSULFONILE DERIVATIVES | |
AR085615A1 (en) | USEFUL FLUOROPIRIDINONE DERIVATIVES AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
AR062797A1 (en) | PIPERIDINE DERIVATIVES AS RENINE INHIBITORS, PHARMACEUTICAL COMPOSITIONS. | |
AR074790A1 (en) | ISOOXAZOL DERIVATIVES SUBSTITUTED, PHARMACEUTICAL COMPOSITIONS AND FOR THE CONTROL OF PARASITES THAT INCLUDE THEM AND THEIR USE IN METHODS TO CONTROL PARASITES IN AND ON HOT BLOOD ANIMALS. | |
AR062786A1 (en) | 2-7-DISPOSED BENZOXASOLS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION METHOD AND USES AS ANTIPROLIFERATIVE AGENTS. | |
CO6361922A2 (en) | HEPATITIS C VIRUS INHIBITORS | |
UY30437A1 (en) | QUINOXALINIL MACROCECLIC INHIBITORS OF SERINE PROTEASE VIRUS OF HEPATITIS C | |
PE20060570A1 (en) | QUINAZOLINE AND ISOQUINOLINE PIPERIDYL COMPOUNDS SUBSTITUTED AS PHOSPHODIESTERASE PDE-10 INHIBITORS | |
AR055592A1 (en) | DERIVATIVES OF 2-AMINO-5-CYCLALKYL-HYDANTOINE AS MODULATORS AND / OR INHIBITORS OF BETA-SECRETASE (BACE) | |
NI200700102A (en) | TETRACICLIC INDOL DERIVATIVES AS ANTIVIRICAL AGENTS | |
PE20060479A1 (en) | HETEROARYL-ARYL-UREAS COMPOUNDS AS KINASE INHIBITORS | |
UY30392A1 (en) | HEPATITIS C PROTEASE INHIBITING MACROCICLIC OXIMYL COMPOUNDS | |
AR086357A1 (en) | INDAZOL DERIVATIVES ACTIVE SUBSTITUTES AS QUINASE INHIBITORS | |
AR057209A1 (en) | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | |
PE20060677A1 (en) | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE AND COMPOSITIONS CONTAINING THEM | |
AR080057A1 (en) | PIRIDINES DISUSTITUTED AS ANTI-BANERIGENS | |
AR049388A1 (en) | HETEROCICLES AS INHIBITORS OF ALDOSTERONA SINTASA | |
AR082111A1 (en) | FUROPIRIDINES OR CONDENSED TENOPIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM USEFUL TO TREAT PSYCHOTIC AND CENTRAL NERVOUS SYSTEM DISORDERS, AND THE SAME PREPARATION METHOD | |
AR086198A1 (en) | REPLACED INHIBITORS OF ACETIL-COA CARBOXYLASE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
UY30387A1 (en) | NEW COMPOUNDS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |